Imaging of tumour hypoxia and metabolism in patients with head and neck squamous cell carcinoma

References

• Harris AL. Hypoxia – a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38–47.
   PubMed Web of Science ®Google Scholar
• Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol 2012;9:674–87.
   PubMed Web of Science ®Google Scholar
• Troost EG, Schinagl DA, Bussink J, Boerman OC, van der Kogel AJ, Oyen WJ, et al. Innovations in radiotherapy planning of head and neck cancers: Role of PET. J Nucl Med 2010;51:66–76.
   PubMed Web of Science ®Google Scholar
• Peeters SG, Zegers CM, Yaromina A, Van Elmpt W, Dubois L, Lambin P. Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles. Q J Nucl Med Mol Imaging 2015;59:39–57.
   PubMed Web of Science ®Google Scholar
• Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 2012;105:21–8.
   PubMed Web of Science ®Google Scholar
• Dubois LJ, Lieuwes NG, Janssen MH, Peeters WJ, Windhorst AD, Walsh JC, et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A 2011;108: 14620–5.
   PubMed Web of Science ®Google Scholar
• Peeters SG, Zegers CM, Lieuwes NG, van Elmpt W, Eriksson J, van Dongen GA, et al. A comparative study of the hypoxia PET tracers [(18)F]HX4, [(18)F]FAZA, and [(18)F]FMISO in a preclinical tumor model. Int J Radiat Oncol Biol Phys 2015;91:351–9.
   PubMed Web of Science ®Google Scholar
• Zegers CM, van Elmpt W, Reymen B, Even AJ, Troost EG, Ollers MC, et al. In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG PET/CT imaging. Clin Cancer Res 2014;20:6389–97.
   PubMed Web of Science ®Google Scholar
• Aerts HJ, van Baardwijk AA, Petit SF, Offermann C, Loon J, Houben R, et al. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy (18)Fluorodeoxyglucose-PET-CT scan. Radiother Oncol 2009; 91:386–92.
   PubMed Web of Science ®Google Scholar
• Due AK, Vogelius IR, Aznar MC, Bentzen SM, Berthelsen AK, Korreman SS et al. Recurrences after intensity modulated radiotherapy for head and neck squamous cell carcinoma more likely to originate from regions with high baseline [18F]-FDG uptake. Radiother Oncol 2014;111:360–5.
   PubMed Web of Science ®Google Scholar
• Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004;4:891–9.
   PubMed Web of Science ®Google Scholar
• Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 2009;324:1029–33.
   PubMed Web of Science ®Google Scholar
• van Loon J, Janssen MH, Ollers M, Aerts HJ, Dubois L, Hochstenbag M, et al. PET imaging of hypoxia using [18F]HX4: A phase I trial. Eur J Nucl Med Mol Imaging 2010;37: 1663–8.
   PubMed Web of Science ®Google Scholar
• Boellaard R, Oyen WJ, Hoekstra CJ, Hoekstra OS, Visser EP, Willemsen AT, et al. The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. Eur J Nucl Med Mol Imaging 2008;35:2320–33.
   PubMed Web of Science ®Google Scholar
• Heukelom J, Hamming O, Bartelink H, Hoebers F, Giralt J, Herlestam T, et al. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer. BMC Cancer 2013;13:84.
   PubMed Web of Science ®Google Scholar
• van Elmpt W, De Ruysscher D, van der Salm A, Lakeman A, van der Stoep J, Emans D, et al. The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. Radiother Oncol 2012;104:67–71.
   PubMed Web of Science ®Google Scholar
• Zimny M, Gagel B, DiMartino E, Hamacher K, Coenen HH, Westhofen M, et al. FDG – a marker of tumour hypoxia? A comparison with [18F]fluoromisonidazole and pO2-polarography in metastatic head and neck cancer. Eur J Nucl Med Mol Imaging 2006;33:1426–31.
   PubMed Web of Science ®Google Scholar
• Sato J, Kitagawa Y, Yamazaki Y, Hata H, Okamoto S, Shiga T, et al. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1alpha expression in oral squamous cell carcinoma. J Nucl Med 2013;54:1060–5.
   PubMed Web of Science ®Google Scholar
• Komar G, Lehtio K, Seppanen M, Eskola O, Levola H, Lindholm P, et al. Prognostic value of tumour blood flow, [(1)(8)F]EF5 and [(1)(8)F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy. Eur J Nucl Med Mol Imaging 2014;41:2042–50.
   PubMed Web of Science ®Google Scholar
• Thorwarth D, Eschmann SM, Holzner F, Paulsen F, Alber M. Combined uptake of [18F]FDG and [18F]FMISO correlates with radiation therapy outcome in head-and-neck cancer patients. Radiother Oncol 2006;80:151–6.
   PubMed Web of Science ®Google Scholar
• Hoeben BA, Bussink J, Troost EG, Oyen WJ, Kaanders JH. Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. Acta Oncol 2013;52:1257–71.
   PubMed Web of Science ®Google Scholar
• Toma-Dasu I, Uhrdin J, Antonovic L, Dasu A, Nuyts S, Dirix P, et al. Dose prescription and treatment planning based on FMISO-PET hypoxia. Acta Oncol 2012;51: 222–30.
   PubMed Web of Science ®Google Scholar
• Chang JH, Wada M, Anderson NJ, Lim Joon D, Lee ST, Gong SJ, et al. Hypoxia-targeted radiotherapy dose painting for head and neck cancer using (18)F-FMISO PET: A biological modeling study. Acta Oncol 2013;52:1723–9.
   PubMed Web of Science ®Google Scholar
• Grau C, Hoyer M, Alber M, Overgaard J, Lindegaard JC, Muren LP. Biology-guided adaptive radiotherapy (BiGART) – more than a vision? Acta Oncol 2013;52:1243–7.
   PubMed Web of Science ®Google Scholar
• Dirix P, Vandecaveye V, De Keyzer F, Stroobants S, Hermans R, Nuyts S. Dose painting in radiotherapy for head and neck squamous cell carcinoma: Value of repeated functional imaging with (18)F-FDG PET, (18)F- fluoromisonidazole PET, diffusion-weighted MRI, and dyna mic contrast-enhanced MRI. J Nucl Med 2009;50:1020–7.
   PubMed Web of Science ®Google Scholar